XML 14 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Oct. 31, 2015
Oct. 31, 2014
Oct. 31, 2015
Oct. 31, 2014
Operating revenue:        
Personalized oncology solutions $ 486 $ 452 $ 971 $ 792
Translational oncology solutions 2,485 1,430 4,822 3,001
Total operating revenue 2,971 1,882 5,793 3,793
Costs and operating expenses:        
Cost of personalized oncology solutions 568 759 1,228 1,516
Cost of translational oncology solutions 1,443 960 3,056 1,924
Research and development 919 1,249 2,019 2,663
Sales and marketing 834 1,203 1,863 2,246
General and administrative 1,700 1,377 3,017 2,831
Total costs and operating expenses 5,464 5,548 11,183 11,180
Loss from operations (2,493) (3,666) (5,390) (7,387)
Other (expense) income:        
Change in fair value of warrant liability 0 625 0 781
Other (expense) (14) (27) (24) (63)
Total other (expense) income (14) 598 (24) 718
Loss before provision for income taxes (2,507) (3,068) (5,414) (6,669)
Provision for income taxes 41 10 47 15
Net loss $ (2,548) $ (3,078) $ (5,461) $ (6,684)
Net loss per common share outstanding        
basic (in dollars per share) $ (0.29) $ (0.55) $ (0.63) $ (1.20)
diluted (in dollars per share) $ (0.29) $ (0.65) $ (0.63) $ (1.32)
Weighted average common shares outstanding        
basic (in shares) 8,702,237 5,573,944 8,702,237 5,573,853
diluted (in shares) 8,702,237 5,654,610 8,702,237 5,654,519